Skip to main content
    1. Home

    • UCB Medicines: Clinical Studies and Scientific Research Publication

    Publications

    This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.

    Select product(s):
    Select topic(s):
    Phase:

    *Includes seizure clusters and acute or prolonged seizures

    164 result(s)

    phase 3

    CIMZIA® (certolizumab pegol)

    Psoriatic Arthritis
    View

    Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumor necrosis factor exposure. 

    Mease P, Deodhar A, Fleischmann R et al.  June 25, 2015
    pre clinical

    FINTEPLA® (fenfluramine)

    Dravet Syndrome
    View

    Pharmacological characterization of an antisense knockdown zebrafish model of Dravet syndrome: inhibition of epileptic seizures by the serotonin agonist fenfluramine

    Yifan Zhang, Angéla Kecskés, Daniëlle Copmans et al.  May 12, 2015
    phase 3

    CIMZIA® (certolizumab pegol)

    Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
    View

    Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis. 

    Sieper J, Landewe R, Rudwaleit M et al.  March 01, 2015
    phase 3

    CIMZIA® (certolizumab pegol)

    Rheumatoid Arthritis
    View

    Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritis. 

    Furst DE, Shaikh SA, Greenwald M et al.  February 01, 2015
    phase 3

    CIMZIA® (certolizumab pegol)

    Crohn's Disease
    View

    Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn’s disease: 7-year results from the PRECiSE 3 study. 

    Sandborn WJ, Lee SD, Randall C et al.  August 22, 2014
    phase 4/RWE

    CIMZIA® (certolizumab pegol)

    Rheumatoid Arthritis
    View

    Rheumatoid arthritis secondary nonresponders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase. 

    Schiff MH, von Kempis J, Goldblum R et al.  June 27, 2014
    phase 3

    CIMZIA® (certolizumab pegol)

    Rheumatoid Arthritis
    View

    Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. 

    Smolen JS, Emery P, Ferraccioli GF et al.  January 15, 2014
    phase 3

    BRIVIACT® (brivaracetam) CV

    Focal Onset Seizures
    View

    Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase 3 randomized, double-blind, placebo-controlled trial

    Victor Biton, Samuel F Berkovic, Bassel Abou-Khalil et al.  November 08, 2013
    phase 3

    BRIVIACT® (brivaracetam) CV

    Focal Onset Seizures
    View

    Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial

    Philippe Ryvlin, Konrad J Werhahn, Barbara Blaszczyk et al.  October 28, 2013
    phase 3

    BRIVIACT® (brivaracetam) CV

    Focal Onset Seizures
    View

    Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase 3, double-blind, randomized, placebo-controlled, flexible-dose trial

    Patrick Kwan, Eugen Trinka, Wim Van Paesschen et al.  October 03, 2013